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Abstract: Temporal lobe epilepsy (TLE) is the most common type of partial epilepsy referred for
surgery due to antiepileptic drug (AED) resistance. A common molecular target for many of
these drugs is the voltage-gated sodium channel (VGSC). The VGSC consists of four domains of
pore-forming α-subunits and two auxiliary β-subunits, several of which have been well studied
in epileptic conditions. However, despite the β4-subunits’ role having been reported in some
neurological conditions, there is little research investigating its potential significance in epilepsy.
Therefore, the purpose of this work was to assess the role of SCN4β in epilepsy by using a combination
of molecular and bioinformatics approaches. We first demonstrated that there was a reduction in the
relative expression of SCN4B in the drug-resistant TLE patients compared to non-epileptic control
specimens, both at the mRNA and protein levels. By analyzing a co-expression network in the
neighborhood of SCN4B we then discovered a linkage between the expression of this gene and K+
channels activated by Ca2+, or K+ two-pore domain channels. Our approach also inferred several
potential effector functions linked to variation in the expression of SCN4B. These observations support
the hypothesis that SCN4B is a key factor in AED-resistant TLE, which could help direct both the
drug selection of TLE treatments and the development of future AEDs.
Keywords: temporal lobe epilepsy; hippocampal sclerosis; antiepileptic drug resistance; SCN4B;
voltage-gated sodium channels; Nav β4 subunit
1. Introduction
Temporal lobe epilepsy (TLE) is one of the most common causes of epilepsy in adults and can arise
sporadically or with a clear familial recurrence [1]. The most common cause of TLE is hippocampal
sclerosis (HS), accounting for ~80% of TLE patients and ~30.5%–45% of all epileptic cases. Other causes
of TLE include benign tumors, vascular malformations, cortical development malformation and
infectious gliosis [1].
The initial approach to the treatment of TLE relies on the administration of antiepileptic drugs
(AEDs); about 60% of TLE patients are responsive to pharmaco-therapies. The remaining 40% are not
responsive to AEDs, despite the use of 2–3 different drug regimens, including combination therapy:
therefore, surgical approaches are considered [2].
In about 70% of cases, surgical resection successfully eliminates or significantly reduces seizure
occurrence. One study found that 14% of the patients following temporal lobe surgery achieved
long-term AED discontinuation, 50% achieved monotherapy and 33% remained on polytherapy [3].
However, this treatment is very invasive and has several undesirable side-effects, given the temporal
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lobes’ role in processing sensory input [4,5]. Furthermore, considering that surgery is not always
successful, it is important to understand why AED resistance occurs in these individuals [6].
Despite our understanding of the binding of many AEDs with their targets, little is known about
how the variable composition of the channels affects both the molecular interaction of AEDs with their
targets and their pharmacological effects. The voltage-gated sodium channels (VGSCs) are perhaps the
most common target for early AEDs and still are mostly used [7].
VGSCs are heteromeric complexes composed of α- and β-subunits. Each α-subunit is associated
with one or more of the four β-subunits, subtypes β1, β2, β3 and β4 [8], which are homologous to cell
adhesion molecules belonging to the Ig superfamily [9]. The β1 and β3 interact with the α-subunit
non-covalently, whereas β2 and β4 associate via disulfide bonds [10].
The mechanism of AED resistance is most probably variable and multifactorial, depending on the
cause along with the drug target [11]. There are several hypotheses to clarify the mechanism for AED
resistance: (I) the multidrug transporter hypothesis shows contradicting evidence [12–14]; (II) the drug
targets are missing, assuming a loss of target sensitivity as being the cause of the AED resistance [15,16];
(III) there is an alteration of drug targets due to polymorphism and transcriptional changes in VGSC
α-subunit previously associated with epilepsy and AED resistance [17,18]. None of these theories have
been fully explained or demonstrated.
The roles of the α-subunits are also well recognized in many channelopathies [19], including
epilepsy [7,20]. Mutations in β1 [21] were associated with AED resistance in animal models, as are
some β-subunits [8], such as SCN2B, SCN3B [22] and SCN4B. Mutations in SCN4B have been reported
in neuropathologies linked with epilepsy [8], such as sudden unexpected death in epilepsy (SUDEP)
and Dravet syndrome [8].
The physiological and pathological significance of β4, which may alter the effects of AEDs
targeting VSCGs, is due to its ability in mediating the fast resurgent sodium current in the cell bodies
of many neurons [23], which in fact helps in determining multiple aspects of VGSC gating [24].
The β4-subunit has been demonstrated to be involved in long-QT syndrome, atrial fibrillation and
neuritic degeneration in patients with Huntington’s disease [25–27], as have the other β-subunits [8,22].
The VGSC β4-subunit is yet to be investigated in human TLE samples, though it has been
demonstrated to be involved in a range of neurological pathologies and in determining the gating of
the channel itself. Hence, the hypothesis was that SCN4B could be impaired in temporal lobe epilepsy
with hippocampal sclerosis (TLE-HS). Therefore, we have investigated the expression modifications in
the transcript SCN4B and the VGSC β4-subunit, the Nav β4 protein, in TLE-HS. We have identified
genes co-expressed with SCN4B in hippocampus of TLE patients from a publicly available dataset.
Functional investigation of the co-expressed genes revealed links to several pathways and components
that have been previously associated to epilepsy, including potassium channels, calcium binding,
mitochondria, metabolism, response to stress and methylation. Such pathways may play important
roles in the pathophysiology associated with the lack of response to sodium channel blocker AEDs.
2. Results
2.1. SCN4B Transcripts Expression in HS and NC Samples
In order to test the hypothesis that SCN4B is differentially expressed in hippocampus of
pharmaco-resistant TLE-HS patients and adjacent (non-epileptic) neocortex tissue (designated as
temporal lobe epilepsy neocortex (TLE-NC)) [28], real-time qPCR analysis was used, and SCN4B
expression was normalized to the house-keeping genes (HKGs). The results from comparing SCN4B
expression in TLE-NC and TLE-HS, by using unpaired analysis, show a decreased expression of SCN4B;
however, this was not statistically significant (p = 0.2247) (Figure 1). When comparing TLE-HS and
TLE-NC across the 11 patient samples, with a paired analysis, SCN4B downregulation in TLE-HS is
statistically significant, with a 43% decrease in expression (p = 0.0244).
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Figure 1. Relative expression level (2−ΔCt) of SCN4B gene, determine using RT-qPCR, in hippocampal 
sclerotic and non-sclerotic tissue samples of each patient. Left panel: unpaired samples. Right panel: 
paired samples. Gene expression levels were calculated using the Ct values of each sample and nor-
malized to the house-keeping genes (PPIA and CDKN). Data are means ± SD, where n = 3 for control 
and epileptic samples of each patient. 
2.2. Western Blot Analysis of Nav β4 in HS and NC Samples 
It is important to determine whether the transcriptional changes determined by qPCR are re-
flected in the protein levels of the SCN4B gene product Nav β4. Therefore, protein extracts from the 
hippocampal non-sclerotic and sclerotic tissue of each patient were subjected to Western blot analy-
sis, staining for Nav β4 (Figure 2a). The normalized band densities were compared between the non-
sclerotic and sclerotic tissue proteins for each patient to determine the relative protein changes in Nav 
β4 (Figure 2b). A reduction in the relative protein expression levels was observed.in sclerotic hippo-
campal tissue compared to non-sclerotic tissue resection. In this case, we used both unpaired and 
paired analysis, and the decrease in TLE-HS was statistically significant for both types of analysis (p 
= 0.0121 and p = 0.0078 for unpaired and paired, respectively). 
Figure 1. Relative expression level (2−∆Ct) of SCN4B gene, determine using RT-qPCR, in hippocampal
sclerotic and non-sclerotic tissue samples of each patient. Left panel: unpaired samples. Right panel:
paired samples. Gene expression levels were calculated using the Ct values of each sample and
normalized to the house-keeping genes (PPIA and CDKN). Data are means ± SD, where n = 3 for
control and epileptic samples of each patient.
2.2. Western Blot Analysis of Nav β4 in HS and NC Samples
It is important to determine whether the transcriptional changes determined by qPCR are
reflected in the protein levels of the SCN4B gene product Nav β4. Therefore, protein extracts from
the hippocampal non-sclerotic and sclerotic tissue of each patient were subjected to Western blot
analysis, staining for Nav β4 (Figure 2a). The normalized band densities were compared between the
non-sclerotic and sclerotic tissue proteins for each patient to determine the relative protein changes in
Nav β4 (Figure 2b). A reduction in the relative protein expression levels was observed.in sclerotic
hippocampal tissue compared to non-sclerotic tissue resection. In this case, we used both unpaired
and paired analysis, and the decrease in TLE-HS was statistically significant for both types of analysis
(p = 0.0121 and p = 0.0078 for unpaired and paired, respectively).
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Figure 2. Qualitative example and quantitative Western blot analysis of β-actin and Nav β4 protein 
expression in sclerotic and non-sclerotic samples of patients with AED-resistant TLE. (a) A Western 
blot analysis of Nav β4 (37 kDa) and β-actin (45 kDa) in sclerotic and non-sclerotic hippocampal tis-
sue. Protein extracts were run on SDS–polyacrylamide gels and analyzed by Western blotting. TLE-
NC, non-sclerotic tissue; TLE-HS, hippocampal sclerotic tissue; L, Chameleon duo prestained protein 
ladder tissue. (b) Relative Nav β4 protein expression level, compared to the β-actin control, as deter-
mine by densitometry. Data are means ± SD, where n = 8 for TLE-HS patients and n = 11 for TLE-NC 
controls. 
2.3. SCN4B Co-Expression Network Analysis in TLE Patients 
After demonstrating that sclerotic hippocampus tissue in drug-resistant TLE patients is charac-
terized by lower expression of SCN4B, both at the mRNA and protein level, we investigated the func-
tional implications of this variability in SCN4B expression. This challenge was addressed by generat-
ing a co-expression network using a publicly available transcriptomics dataset from TLE hippocam-
pus samples, followed by the investigation of functional aspects of genes significantly co-expressed 
with SCN4B. A total of 83 genes were found significantly co-expressed with SCN4B (i.e., FDR < 0.05 
and posterior probability > 0.8), but only 77 genes contained functional information available. 
Using information retrieved from both DAVID and AmiGO 2, we have annotated relevant GO 
terms associated to co-expressed genes and have identified several biological mechanisms and com-
ponents associated to these genes, including components closely related to neuronal function such as 
potassium ion channels (Figure 3). Additionally, seven of the co-expressed genes were previously 
found associated to epilepsy, which seems to be associated to a diversity of biological mechanisms 
(hormone-based signaling, mitochondria, metabolism, potassium ion channels, methylation and re-
sponse to stress). DAVID analysis found no enriched pathways for SCN4B co-expressed genes. In 
contrast, STRING analysis found that calcium-activated potassium channel activity GO term 
(GO:0015269) was significantly enriched (FDR = 0.0374) due to KCNMA1, KCNMB1 and KCNT2 
genes. 
Figure 2. Qualitative example and quantitative Western blot analysis of β-actin and Nav β4 protein
expres ion in sclerotic and non-sclerotic samples of patients with AED-resistant TLE. (a) A Western
blot analysi of Nav β4 (37 kDa) and β-actin (45 kDa) in sclerotic and on-sclerotic hippocampal tissue.
Protein extracts were run on SDS–polyacrylamide gels and analyzed by Western blotting. TLE-NC,
non-sclerotic tissue; TLE-HS, hippocam al sclerotic tissue; L, Chameleon duo prestained protein ladd r
tissue. (b) Relative Nav β4 protein expr ssion level, compared to the β-ac in control, as determine by
densitometry. Data a e me ns ± SD, where n = 8 fo TLE-HS patients and n = 11 for TLE-NC controls.
2.3. SCN4B Co-Expression Network Analysis in TLE Patients
After demonstrat ng that sclerotic hippocampus tissue in drug-resistant TLE patients is
characterized by lower expression of SCN4B, both at the mRNA and protein level, we investigated
the functional implications of this variability in SCN4B expression. This challenge was addressed
by generating a co-expression network using a publicly available transcriptomics dataset from TLE
hippocampus samples, followed by the investigation of functional aspects of genes significantly
co-expressed with SCN4B. A total of 83 genes were found significantly co-expressed with SCN4B
(i.e., FDR < 0.05 and posterior probability > 0.8), but only 77 genes contained functional
information available.
Using information retrieved from both DAVID and AmiGO 2, we have annotated relevant
GO terms associated to co-expressed genes and have identified several biological mechanisms and
components associated to these genes, including components closely related to neuronal function such
as potassium ion channels (Figure 3). Additionally, seven of the co-expressed genes were previously
found associated to epilepsy, which seems to be associated to a diversity of biological mechanisms
(hormone-based signaling, mitochondria, metabolism, potassium ion channels, methylation and
response to stress). DAVID analysis found no enriched pathways for SCN4B co-expressed genes.
In contrast, STRING analysis found that calcium-activated potassium channel activity GO term
(GO:0015269) was significantly enriched (FDR = 0.0374) due to KCNMA1, KCNMB1 and KCNT2 genes.
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Figure 3. Scheme summarizing 77 genes co-expressed with SCN4B (FDR < 0.05) and their functional
annotation. An overview of their functional groups is presented on yellow boxes, based on associated
gene ontology terms. Blue nodes indicate genes previously associated to epilepsy according to
DisGeNET database. Green edges indicate negative correlation, while magenta edges indicate positive
correlation. Blue lines: positive co-expression. Purple lines: negative co-expression.
3. Discussion
In this study, patients affected by mesial TLE were compared with an adjacent specimen
from non-seizing medial temporal neocortex tissue, mesial TLE-NC. The experiments demonstrate
a reduction in the expression profile, at a transcriptional and translational level, in the voltage-gated
sodium channel β4-subunit in the sclerotic hippocampal tissue of AED-resistant TLE compared with
TLE-NC. Changes in mRNA expression levels are not always reflected in the protein expression, but
our results demonstrate a borderline correlation. This evidence potentially elucidates a key factor of
AED resistance. The β4-subunit plays an important role in determining the gating of the VGSC and
can therefore affect the binding sensitivities of AED, many of which act in a use-dependent manner.
A reduction in the Nav β4 could simply result in a loss of drug action on the target channel,
contributing to AED resistance in TLE patients. However, theβ4-subunit has already been shown in cell
models to favor the open state of VGSCs and promote persistent currents with certain α-subunits [29].
Therefore, a reduction is more likely to result in a decrease in the frequency and duration of VGSC
in the resting state, which would reduce the opportunity for the vast number of use-dependent
VGSC-modulating AEDs to bind to their target.
The combination of β-subunits defines a range of VGSC current amplitudes. Co-expression of
β1 with β4 can in fact suppress the gating effects of β4 mentioned previously. This is a result of
β1-subunits’ own effect on VGSC gating, which instead stabilizes the closed states at hyperpolarized
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potentials and inactivated states at depolarized potentials [29]. Therefore, a pathology, like TLE-HS,
that results in a reduction of β4 in an area of the brain that would usually express β4, would in fact
have an enhanced effect. There would be a loss in the favor of the open/resting state of VGSCs caused
by β4 association and an increase in the effects of β1 on the VGSC gating, which are usually partially
suppressed through co-expression with β4. In turn, these increased effects of β1 would further reduce
the binding of AEDs to VGSCs.
Despite understanding the possible influence that a reduction in β4 may have on AED resistance,
it is important to identify the cause of this lower expression to help discover new molecular targets to
manipulate β4 expression. These experiments do not allow us to determine why these changes occur.
They could be a result of epilepsy or the sclerosis. Other types of epilepsy, with and without sclerotic
tissue, and other pathologies associated with the formation of sclerotic tissue, like multiple sclerosis
(MS), would need to be analyzed in order to develop our understanding of a potential cause for this
reduction in β4.
Another approach that could help further direct this research is the determination of whether
there are mutations in the SCN4B promoter site in TLE-HS patients. Methylation and acetylation
patterns should also be investigated, as these may result in altered β4 expression levels, but they are
yet to be investigated in any of the β-subunits. Nevertheless, increased expression patterns of DNA
methyltransferase (DNMT) isoforms DNMT1 and DNMT3 [30] and histone deacetylases (HDAC2) [31]
have been found in our analysis in TLE. Our data also show two more genes co-expressed with SCN4B:
methionine synthase reductase (MTRR) and diphthine synthase (DPH5). They are both involved with
the methylation process in neurons, and they show opposite co-expression with SCN4B, MTRR with
a positive and DPH5 with a negative co-expression. MTRR was already investigated in epilepsy, [32],
whereas DPH5 has been linked to the translation elongation factor 2 but has not been investigated yet
in TLE, and this could lead to significant modulation of the translational regulatory machinery.
Mutations in other β-subunits have already been found. For example, heterozygous mutations in
extracellular domain of SCN1B [33] and several additional mutations have all been associated with
epilepsy [33–37]. Therefore, it appears reasonable to hypothesize that mutations affecting the structure
and expression of β4 may be present in epilepsy, including TLE.
The diffused expression of Nav1.2 along some demyelinated axons supports recovery of action
potential conduction. Polymorphisms in the SCN2A, which may reduce this recovery action, have
been associated with epilepsy and AED resistance [18]. In contrast, Nav1.6 produces Na+ current that
can drive the Na+–Ca2+ exchanger, potentially triggering injurious cascades and promoting neuronal
atrophy [38]. Seizures also result in an increase in Na+ currents, which also drives neuronal atrophy:
‘seizure-induced neuronal atrophy’ [39]. Therefore, genetic and expressional changes in β4, along with
other VGSC-subunits, in TLE could alter the gating of VGSCs and may alter the neuroprotective activity
of the VGSCs in the neuronal atrophy seen in the formation of sclerosis. When considered along with
the inflammatory abnormalities seen in TLE [40], this suggests that TLE drives the formation of HS in
predisposed neuronal tissue.
Interestingly, the β-secretase, β-site APP-cleaving enzyme 1 (BACE1), has shown, in Purkinje
neurons, to have a novel function in the regulation of neuronal excitability by impairing the regular
processing of β4 [41–43]. The mechanism behind transcriptional regulation of SCN4B remains elusive.
However, it is noted that BACE1 is known to have some transcriptional effects. Tts involvement
in proteolytic cleaving of β1 is proposed to release a soluble intracellular domain of β1 which then
enhances transcription of α-subunit genes, thus demonstrating the need to investigate any effects
BACE1 may have on β4 transcription as well as protein cleavage. When the potential effects of
BACE1 in sclerosis are combined with the loss of neuroprotective activity, the effects could result in
the significant reduction of β4 and, hence, a reduction in the VGSCs susceptible to AED interaction.
Alternatively, it may only be one of these mechanisms that results in a reduction of β4, but they would
cause a reduction nonetheless.
Int. J. Mol. Sci. 2020, 21, 2955 7 of 14
AED resistance is likely to be multifactorial, which was demonstrated by VGSC mutations
associated with AED resistance [17,18,21] and the altered expression of receptors [44]. This research
elucidates the reduced expression of β4 as an important factor in the AED resistance seen in TLE-HS
and could therefore direct both our current approach to the treatment of AED-resistant TLE and the
development of novel AEDs in the future. The large number of AEDs with known VGSC-modulating
properties, even in the small sample cohort used in this study, Table 1, helps signify the potential
impact that a change in this molecular target might actually have on the approach to treating TLE.
Table 1. Clinical data of patient samples.
Patients Gender
Age at
Surgery
(years)
Duration of
Epilepsy
(years)
Sample
Side Current AED Previous AEDs
Pt. 13 F 24 23 TLE-HS (Lt) LCS, LEV CBZ *, LMT *
Pt. 18 M 48 47 TLE-HS (Rt)TLE-NC (Rt)
PHT, LEV, LMT,
GBP,
TPM, PGB, ZNS
PHT *, LEV,
LMT *, GBP,
TPM *, PGB, ZNS
Pt. 21 M 32 3 TLE-HS (Rt)TLE-NC (Rt) LMT, OXC CBZ *, LEV
Pt 24 F 54 53 TLE-HS (Lt)TLE-NC (Lt) LMT, PGB
GBP, VPA *,
PHT *, CBZ *,
PB, LEV, CNP, LCS
Pt 27 F 27 6 TLE-HS (Lt)TLE-NC (Lt) NA NA
Pt. 31 F 44 10 TLE-HS (Lt) LCS, LEV, PHT OXC *, LMT *
Pt. 33 M 35 14 TLE-HS (Lt) LMT, CLB VPA *, ZNS, CBZ *
Pt. 39 M 33 31 TLE-HS (Lt) LEV, LMT* CBZ*, VPA*, CLB
Pt. 41 F 39 37 TLE-HS (Rt) None GBP *, LEV, LMT *CBZ *, LMT *, VPA *
Pt. 46 M 48 41 TLE-HS (Rt) None PHT *, VGB, CLB,TPM *, TGB
Pt. 47 M 48 NA TLE-HS (Lt) NA OXC *
CBZ, Carbamazepine; CNP, Clonazepam; GBP, Gabapentin; LEV, Levetiracetam; LMT, Lamotrigine; OXC,
Oxcarbazepine; PB, Phenobarbital; PER, Perampanel; PGB, Pregabalin, PHT, Phenytoin; TGB, Tiagabine; TPM,
Topiramate; VGB, Vigabatrin; VPA, Valproate. NA: not available. *AEDs with VGSC-modulating properties.
Our network analysis using publicly available data revealed that important cellular (neuronal and
glial) functions and pathways are indeed defining the phenotype of TLE in the AED-resistant cohort.
This has allowed us to determine a principal element to be further investigated in order to improve
the response to sodium channel blockers as therapeutics for TLE. Despite the analysis being more
focused on the β1-subunit, it has been reported that sodium β channel subunits are multifunctional
and act via multiple signaling pathways. This was shown in an animal model with induced mutations
and by genetic characterization derived from epileptic patients affected by Dravet syndrome (DS),
generalized epilepsy with febrile seizures plus (GEFS+), sudden infant death syndrome (SIDS) and
sudden unexpected death in epilepsy (SUDEP) [8].
Differently, we have defined most, if not all, of these pathways focusing on sodium channel
β4-subunit and in human brains affected by TLE (Figure 4).
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Figure 4. Putative mechanism involving SCN4B (IPA findings). Molecules with a red star are
co-expressed with SCN4B. Figure produced using Ingenuity Pathway Analysis (IPA) (QIAGEN Inc.,
https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis).
The pathways that we have identified by SCN4B co-expression network analysis in TLE patients
can be used to generate hypotheses of the mechanisms linked to impairment in the expression of SCN4B.
These include the modulation, trafficking and localization of the sodium channel itself, the cellular
migration and proliferation including the cytoskeleton, linking it to development phenomena; pathways
which involve DNA regulation, repair/binding and transcription; and pathways involving protein
binding and signal transduction.
Several SCN4B co-expressed genes are related to mitochondrial function, and its impairment
has been identified as a potential cause of epileptic seizures [45]. One of these mitochondria-related
genes is CA5A (carbonic anhydrase 5A), which has a positive co-expression with SCN4B. Several
EDs act through multiple mechanisms and simultaneously inhibit carbonic anhydrases and block
VGSCs [44]. This example could point that other effects associated to the lower expression of
SCN4B, in this case a correlated lower expression of CA5A, could simultaneously contribute to AED
resistance. Mitochondrial disorders are often the cause of seizures, and diverse types of seizures
have been reported to be associated with mitochondrial oxidative stress, which gradually disrupts the
homeostasis of intracellular Ca2+. Mutations have been reported in HSD17B10, impairing the activities
of the mitochondrial RNase P complex [46].
Interestingly, SCN4B was shown to be negatively co-expressed with two calcium-activated
potassium channel genes (KCNMA1 and KCNMB1) and a two-pore potassium channel (KCNK2) and
positively co-expressed with a sodium-activated potassium channel gene (KCNT2).
The KCNMA1, KCNMB1, and KCN2 genes have a main role in stopping or reducing excitatory
stimuli in neurons [47]. Therefore, from these results, we can hypothesize that when SCN4B is
dysregulated these sodium- and potassium-activated channel, they lose their inhibitory role, leading
to the TLE.
There have been no previous associations of SCN4B with these potassium channel genes; therefore,
the cause of their co-expression in TLE patients is unclear. Nevertheless, by using IPA to investigate
possible pathways to link SCN4B to these potassium channel genes, we have found that SCN2A, which
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binds to SCN4B to form the sodium channel, also binds to Ca2+/calmodulin complexes. Mutations in
SCN2A cause Ca2+ to dissociate from calmodulin, leading to higher intracellular Ca2+ concentration,
and these changes could in turn have a downstream effect in the expression of calcium-activated
potassium channels. One hypothesis is that the lower expression of SCN4B could also affect the ability
of SCN2A to bind to Ca2+/calmodulin complexes. Interestingly, changes in KCNMA1 expression and
in intracellular Ca2+ concentration also have an effect on POMC regulation and intra/extracellular
concentrations of its products. POMC was also found to be co-expressed with SCN4B in our analysis,
and it has been previously associated to epilepsy. The intracellular neuropeptide alpha-melanocyte
stimulating hormone (alpha-MSH) POMC product increases Ca2+ level. Depletion of extracellular
Ca2+ decreases adrenocorticotropic hormone (ACTH) POMC product release.
There is still much to uncover about biological mechanisms in which SCN4B is involved and
its role in AED resistance. This functional analysis of putative systems affecting or affected by
SCN4B expression, despite the limited sample size, points to avenues that can be explored for further
understanding of AED resistance and potential candidate drug targets to be considered.
4. Materials and Methods
4.1. Tissue Collection
Tissue from the hippocampal formation was obtained from pharmaco-resistant mesial TLE-HS
(n = 19) patients and adjacent (non-epileptic) medial temporal neocortex tissue TLE-NC (n = 15) [28],
from Sheffield Hallamshire Hospital (Table 1). Informed consent was given by all participants for
experimental use; approved by South Yorkshire NRES committee York and Humber (08-H1310-49).
TLE-HS and TLE-NC sample pairs were from the same patient, therefore eliminating
inter-individual, age-related, postmortem-related and drug-related variabilities.
4.2. qRT-PCR Analysis of SCN4B
The quantification of mRNA levels of SCN4B was performed by qRT-PCR in TLE-NC (n = 11) and
TLE-HS (n = 19) samples. The mRNA was extracted from the epileptic patient samples and purified
using the SV Total RNA Isolation System (Promega, UK), and then the product was quantified using
the Nano Assay (Nanodrop Analyzer, Thermofisher, Loughborough, UK). The reverse transcription of
each mRNA sample was done using 1µg of RNA with the Superscript III First-stand kit (Qiagen, UK).
Gene expression levels were then determined using the TaqMan Fast Universal MasterMix (Applied
Biosystem, Life Technologies, Loughborough, UK) with the StepOnePlus Real-Time PCR System
(Applied Biosystems, Thermo Fisher, UK). Real-time qPCR reactions were run over 50 cycles (initial
heating of 95 ◦C for 20 s followed by cycles of 95 ◦C for 1 s and 20 s at 60 ◦C) with 20 ng of cDNA per
reaction to amplify specific genetic sequences. The following primers were used to detect specific
house-keeping genes (HKGs): peptidylprolyl isomerase A (PPIA) (Hs04194521_s1, Applied Biosystems,
Life Technologies, UK) and cyclin-dependent kinase inhibitor 1B (CDKN1B) (Applied Biosystems, Life
Technologies, UK). These results were utilized to normalize the gene expression levels of the target
gene, SCN4B (Hs03681025_m1, Applied Biosystems, Life Technologies, UK). All samples were run
in triplicate, and only the reactions that produced appropriate amplification curves were analyzed,
as produced by the real-time qPCR analytical software (StepOne Software v2.0 (Applied Biosystems,
Thermo Fisher, UK)). Relative expression of SCN4β compared to an average of the HKG expression
was calculated using the 2−∆Ct and 2−∆∆Ct methods.
4.3. Western Blot Analysis of Nav β4
Tissue samples were lysed using 200 mg/mL CellLytic MT Mammalian Tissue Lysis/Extraction
Regent (Sigma, Welwyn Garden City, UK) and 1 mg/mL stock protease inhibitor cocktail (Sigma, UK)
to extract protein. Protein concentration was determined using a bicinchoninic acid (Sigma, UK) assay.
The protein samples were then subjected to electrophoresis and separated on a 10% polyacrylamide
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gel, using 30 µg of protein per lane, alongside the molecular weight marker, Chameleon (Life Sciences,
Applied Biosystems). The gel was then blotted onto a nitrocellulose blotting membrane, Amersham
Protan supported 45 µm NC (GE Healthcare, Life Technologies, Little Chalfont, UK), using 75 V
(~180 mA) (PowerPac Basic, BioRad, Deeside, UK) for 50 min in transfer buffer (25 mM Tris, 193 mM
glycine, 10% methanol made up with water). Then, the blot was incubated overnight in blocking
solution (5% non-fat powdered milk in TBST (10 mM Tris, pH 7.5, 50 mM NaCl and 0.05% Tween-20,
(Sigma)). After blocking, the blots were incubated at room temperature for 1 h in the primary antibody
solution; rabbit anti-SCN4B (1:500) (ab80539, Abcam, Cambridge, UK) and β-actin (8H10D10) mouse
mAb (1:1000) (Santa Cruz, Harrogate, UK) diluted in blocking solution. The blots were washed three
times, each for 10 min, in TBST. Primary antibody binding was detected by incubation with a solution
of 1:10,000 dilution of infrared IRDye (800 CW)-conjugated donkey anti-rabbit (LI-COR Biosciences,
Cambridge, UK) and 1:50,000 dilution of infrared IRDye (680 CW)-conjugated donkey anti-mouse
(LI-COR biosciences, Cambridge, UK) in 5% powdered milk in TBST, for 1 h at room temperature.
Again, the blots were washed three times, each for 10 min, in TBST. Blots were visualized and quantified
using Odyssey LI-COR Scanner (LI-COR Biosciences, Cambridge, UK).
4.4. Western Blot Band Quantification
The protein band densities on the Western blots, as detected by the Odyssey LI-COR scanner
(LI-COR Biosciences), were quantitated using the Image Studio software (Ver3.1, Applied Biosystems).
The protein bands of interest in each sample, corresponding to the Nav β4 protein (37 kDa), were
normalized to β-actin (42kDa) band density, and relative intensities were calculated to run comparative
analysis between the sclerotic and control (non-sclerotic) samples.
4.5. Statistical Analysis of SCN4B Gene Expression and Nav β4 Band Intensities
The changes in SCN4B gene expression and Nav β4 protein expression between sclerotic and
control samples were analyzed for statistical significance using Mann–Whitney U test for the unpaired
data sets. Wilcoxon’s signed ranks test was used for statistical paired analysis.
Comparative analysis, investigating correlation between the SCN4B and Nav β4 expression level,
was performed using Spearman’s rank test to produce a correlation coefficient (strong correlation
when r ≥ 0.7).
4.6. SCN4B Co-Expression Network Analysis in TLE Patients
Microarray expression profiles from 129 TLE patients (GEO ID: GSE63808) were used for inferring
co-expression networks [47]. To increase the power for detecting significant correlations, probes
were filtered by expression level (probes showing a detection p-value < 0.05 in at least 20% of the
samples) and expression variation (probes having a coefficient of variation (CV) of gene expression
greater than the median CV calculated across all probes in the set). After filtering and collapsing
probes to gene level, a total of 7475 remaining genes were used as input for co-expression network
inference using Graphic Gaussian Models (GGM) [48] method through the “GeneNet” [49] package in R
(http://www.r-project.org/). This method estimates partial correlations within the probe set, identifying
co-expression between probe pairs, while removing effects from other probes. A mixture model is then
fitted to the partial correlations for assessing significant edges in the network.
4.7. Functional Analysis of SCN4B Co-Expressed Genes
We used DAVID v6.8 [50] and STRING web tools to perform functional enrichment analysis [51].
We also used Ingenuity Pathwy Analysis (IPA) (QIAGEN Inc., https://www.qiagenbioinformatics.
com/products/ingenuity-pathway-analysis) [52] to investigate putative pathways linking SCN4β to
co-expressed genes. IPA built-in tools, such as ‘Connect’, ‘Path Explorer’ and ‘Grow’ search for
connections between selected molecules based on prior knowledge. Genes previously associated with
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epilepsy were retrieved from DisGeNet [53] database v6.0 (disease ID: C0014544). We also searched
AmiGO 2 [54,55] database v2.5.12 for gene ontology (GO) terms associated to co-expressed genes.
5. Conclusions
It may be possible to specifically target the β4-subunit of sodium channels; as it only shares 35%
amino acid identity with the most closely associated β2-subunit, it would be more effective to induce
an overall increasing expression of β4, rather than to modulate the relatively few β4-subunits that
are still present. Investigations into mutations and the transcriptional regulation of SCN4B would be
needed to elucidate potential targets for modulating SCN4B expression and the pathways it influences.
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